What is the effect of breast cancer patients taking the targeted drug lapatinib?

Lapatinib is an oral, small molecule tyrosine kinase inhibitor that mainly targetsHER2 (human epidermal growth factor receptor2< span>) and EGFR (epidermal growth factor receptor), for patients with HER2-positive advanced or metastatic breast cancer. Unlike traditional single-target anti-HER2 antibody treatments (such as trastuzumab), lapatinib can simultaneously inhibit the signaling pathways in tumor cells, thereby blocking the proliferation and survival of tumor cells and presenting a new treatment option for some drug-resistant patients.

Clinical studies have shown that lapatinib combined with capecitabine (Capecitabine) can significantly improve the treatment of patients with HER2 positive advanced breast cancer. It is effective in prolonging progression-free survival (PFS) and overall survival (OS), especially for patients whose disease still progresses after treatment with trastuzumab. For example, the EGF100151 study showed that the risk of disease progression in the lapatinib combination treatment group decreased by nearly 50%. This demonstrates its unique value in overcoming trastuzumab resistance.

In addition, lapatinib has shown certain advantages in the treatment of brain metastatic breast cancer. Because its molecules are small and can pass through the blood-brain barrier, it can act on metastatic lesions in the central nervous system. Multiple studies have found that lapatinib combined with other drugs to treat patients with brain metastases can delay the progression of intracranial lesions, and some patients even experience tumor shrinkage. This is rare among other HER2-targeted drugs, bringing new hope to advanced patients.

Overall, lapatinib provides an additional treatment option for patients with HER2positive breast cancer, especially in the setting of disease progression or the presence of brain metastases. However, the efficacy is limited by HER2 status, patient tolerance and combination medication regimens, and common adverse reactions include diarrhea, rash, decreased appetite, etc. Therefore, before using lapatinib, patients should undergo HER2 testing and individualized evaluation under the guidance of a doctor to formulate a scientific treatment strategy.

Reference materials:https://www.drugs.com/